Guy's and St Thomas' Hospital, London SE1 7EH, UK.
J Hosp Infect. 2009 Dec;73(4):323-30. doi: 10.1016/j.jhin.2009.05.008. Epub 2009 Aug 22.
Formerly an under-appreciated iatrogenic infection, catheter-related bloodstream infections (CRBSIs) are now the focus of considerable preventive strategies. Although robust clinical definitions remain elusive due to the difficulty in identifying the focus of infection in hospitalised patients, surveillance definitions are proving useful to monitor and compare institutional rates of CRBSI and to target infection control resources. New catheter-sparing diagnostic techniques have been developed, that are probably most applicable to assessment of infection in stable ambulatory patients with single long-term tunnelled catheters rather than acutely unwell hospitalised patients. There is an impressive body of evidence that can be used to support implementation, surveillance and audit of basic infection control practices that should help institutions reduce CRBSI rates. The introduction of preventive antimicrobial strategies at the catheter site has been recommended by international guidelines, yet there remains justifiable concern about long-term selection of resistant organisms. This has not been adequately addressed in current studies. Economic analyses require data on the clinical effect of CRBSIs to adequately assess the benefit; such data are scarce, owing to the difficulty in assessing the contribution from comorbidities, with consequential conflicting results. Overall, institutions can justifiably first assess the benefit of a sustained programme of re-enforcing basic infection control practice on CRBSI before assessing whether the introduction of additional preventive antimicrobial strategies are likely to have any benefit.
从前,导管相关血流感染(CRBSI)被认为是一种被低估的医源性感染,现在已成为许多预防策略的重点。尽管由于难以确定住院患者感染的焦点,因此仍难以确定稳健的临床定义,但监测定义被证明对于监测和比较机构的 CRBSI 率以及针对感染控制资源非常有用。已经开发出了新的、无需留置导管的诊断技术,这些技术可能最适用于评估稳定的门诊患者中单个长期隧道导管的感染,而不是急性不适的住院患者。有大量证据可以支持实施、监测和审核基本感染控制实践,这有助于机构降低 CRBSI 率。国际指南建议在导管部位采用预防性抗菌策略,但长期选择耐药菌的问题仍令人担忧。目前的研究尚未充分解决这一问题。经济分析需要有关 CRBSI 临床效果的数据来充分评估其益处;由于难以评估合并症的贡献,因此此类数据很少,因此结果存在冲突。总体而言,机构可以合理地首先评估强化基本感染控制实践计划对 CRBSI 的益处,然后再评估是否引入其他预防抗菌策略可能会有任何益处。